Australia’s biggest vitamins group Blackmores has paid $10 million for a stake in a company commercialising medical treatments derived from microorganisms in the human gut, as it looks to gain a bigger foothold in the $7 billion global probiotics market.
Blackmores, now part of Japanese conglomerate Kirin’s empire, has acquired a 14 per cent interest in BiomeBank in a deal which valued the Adelaide-based biotech at $60 million.
Loading…